Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 04.05.2026 1 Anal Chem 3 Anticancer Res 1 Arch Immunol Ther Exp (Warsz) 1 Biochem Biophys Rep 1 Biol Direct 1 Biomol Ther (Seoul) 1 BJU Int 1 BJUI Compass 1 BMC Med Imaging 1 BMC Urol 1 Braz J Med Biol Res 1 Cancer Genomics Proteomics 1 Cancer Metastasis Rev 1 Cancer Rep (Hoboken) 1 Cancer Treat Res Commun 1 Chem Biol Interact 2 Clin Genitourin Cancer 1 Comput Biol Chem 1 Curr Issues Mol Biol 2 Curr Oncol 1 Cyborg Bionic Syst 1 Discov Oncol 1 Eur J Oncol Nurs 1 Eur Urol 1 Eur Urol Oncol 1 Front Bioeng Biotechnol 1 Front Immunol 2 Front Oncol 1 Future Oncol 2 Histopathology 1 IEEE Trans Comput Biol Bioinform 1 In Vivo 1 Indian J Tuberc 1 Int J Cancer 1 Int J Urol 1 Int Urol Nephrol 3 Investig Clin Urol 1 J Int Med Res 1 J Mater Chem B 1 J Med Econ 2 J Nanobiotechnology 1 J Natl Compr Canc Netw 1 J Pers Med 2 J Urol 1 JCO Glob Oncol 1 JMIR Res Protoc 1 Jpn J Clin Oncol 1 Nat Commun 1 Nat Rev Urol 1 Nutr Cancer 1 Pathol Res Pract 1 PeerJ 1 Photodiagnosis Photodyn Ther 1 Proteomics 1 Sci Rep 1 Tech Innov Patient Support Radiat Oncol 1 Urol Int 3 Urologia 1 Zhong Nan Da Xue Xue Bao Yi Xue Ban

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Anal Chem

1. YIN L, Wang R, Guo FL, Han X, et al
   One-Step Urinary EV Capture-to-SERS on a Temperature-Responsive AuEIH Substrate with Transformer-Based Urologic Cancer Classification.
   Anal Chem. 2026;98:12035-12043.
   PubMed         Abstract available
   
   

   
   Anticancer Res

2. GOTO K, Ando K, Motoi N, Iizuka T, et al
   Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer.
   Anticancer Res. 2026;46:2445-2453.
   PubMed         Abstract available
   
   
3. THI TN, Nguyen VT, Thanh HD, Kwon SY, et al
   Inhibition of AP-1 Reduces CD46-mediated Invasion of Bladder and Colon Cancer Cells.
   Anticancer Res. 2026;46:2525-2539.
   PubMed         Abstract available
   
   
4. FURUBAYASHI N, Tsujita J, Takayama A, Shiraishi Y, et al
   Real-world Delivery and Outcomes of Intravesical BCG for Non-muscle-invasive Bladder Cancer.
   Anticancer Res. 2026;46:2599-2608.
   PubMed         Abstract available
   
   

   
   Arch Immunol Ther Exp (Warsz)

5. HU J, Li B, Xu X, Lin S, et al
   Fusobacterium nucleatum Promotes Bladder Cancer Development Through lncRNA IDH1-AS1-Mediated Autophagy.
   Arch Immunol Ther Exp (Warsz). 2026;74.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Rep

6. SAEED AK, Triantafyllakis P, Gordon NS, James ND, et al
   The role of HAI-1 in urothelial bladder cancer: Tissue expression, ectodomain shedding and clinical outcomes.
   Biochem Biophys Rep. 2026;46:102600.
   PubMed         Abstract available
   
   

   
   Biol Direct

7. HSIEH TH, Kuo HP, Pan CH, Lin YC, et al
   A cyclin D1-CDK4/6-E2F dependency represents an acquired vulnerability in cisplatin-resistant bladder cancer.
   Biol Direct. 2026 Apr 27. doi: 10.1186/s13062-026-00812.
   PubMed        
   
   

   
   Biomol Ther (Seoul)

8. PARK C, Cha HJ, Hong SH, Kim HS, et al
   Combination Therapy with Betulinic Acid and TRAIL Increases ROS-Dependent Cytotoxicity and Inhibits PI3K/Akt Signaling in Human Bladder Cancer Cells.
   Biomol Ther (Seoul). 2026;34:641-651.
   PubMed         Abstract available
   
   

   
   BJU Int

9. PACKIAM VT, Black PC, Catto JWF, Ghodoussipour S, et al
   'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026.
   BJU Int. 2026 Apr 28. doi: 10.1111/bju.70299.
   PubMed        
   
   

   
   BJUI Compass

10. LIM S, Standish L, Liu H, Paul E, et al
    Lymph node dissection during cystectomy for non-muscle-invasive bladder cancer: A systematic review.
    BJUI Compass. 2026;7:e70201.
    PubMed         Abstract available
    
    

    
    BMC Med Imaging

11. LV J, Yang P, Zheng W, Huang D, et al
    Predicting muscle-invasive bladder cancer with dual-layer detector spectral CT-derived extracellular volume fraction.
    BMC Med Imaging. 2026 Apr 24. doi: 10.1186/s12880-026-02342.
    PubMed        
    
    

    
    BMC Urol

12. SINGH G, Kumar A, Kumar L, Mishra N, et al
    Urinary exosomal miRNA profiling reveals sensitive non-invasive detection of bladder cancer.
    BMC Urol. 2026 Apr 29. doi: 10.1186/s12894-026-02130.
    PubMed        
    
    

    
    Braz J Med Biol Res

13. CORTES J, Trindade Filho JCS, Rogatto SR
    The emerging role of the microbiome in bladder cancer: prognostic implications and treatment response.
    Braz J Med Biol Res. 2026;59:e15526.
    PubMed         Abstract available
    
    

    
    Cancer Genomics Proteomics

14. KANG J, Lee HJ, Oh SB, Nam JK, et al
    Transcriptome-based Deep Learning Model for Predicting Gemcitabine and Cisplatin Chemotherapy Response in Urothelial Carcinoma: Development and External Validation.
    Cancer Genomics Proteomics. 2026;23:546-557.
    PubMed         Abstract available
    
    

    
    Cancer Metastasis Rev

15. DER B, Varadi M, Nagy N, Kubik A, et al
    Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.
    Cancer Metastasis Rev. 2026;45:26.
    PubMed         Abstract available
    
    

    
    Cancer Rep (Hoboken)

16. MOUSAVI SE, Antar RM, Aslani A, Shokri P, et al
    Bladder Cancer Incidence Trends in the United States From 2000 to 2020.
    Cancer Rep (Hoboken). 2026;9:e70548.
    PubMed         Abstract available
    
    

    
    Cancer Treat Res Commun

17. CHAMGORDANI PR, Taghiyar S, Abedinzadeh M, Shahanipour K, et al
    Urinary mRNA profiling of autophagy-related genes ATG5, ATG7, MAP1LC3B, and mTOR in non-muscle invasive bladder cancer (NMIBC).
    Cancer Treat Res Commun. 2026;47:101178.
    PubMed         Abstract available
    
    

    
    Chem Biol Interact

18. SUN M, Hu D, Li T, Chen Z, et al
    Multidimensional transcriptomic analysis and in vitro experiments dissect the landscape of 2',2',4',4'-Tetrabromodiphenyl ether in bladder cancer progression.
    Chem Biol Interact. 2026;434:112079.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

19. KRAVCHUK A, Garzaro JRR, Wirtz R, Wolff I, et al
    Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.
    Clin Genitourin Cancer. 2026 Apr 1:102554. doi: 10.1016/j.clgc.2026.102554.
    PubMed         Abstract available
    
    
20. KIM D, Ged Y, Grivas P, Singh P, et al
    Association Between Proto-Oncogene N-RAS Transcript Level and Overall Survival in Node-Negative Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026 Apr 1:102557. doi: 10.1016/j.clgc.2026.102557.
    PubMed         Abstract available
    
    

    
    Comput Biol Chem

21. WU G, Yu W, Yao D, Ma X, et al
    A computational framework identifies a matrisome-related gene signature for bladder cancer prognosis and prioritizes candidate compounds.
    Comput Biol Chem. 2026;124.
    PubMed         Abstract available
    
    

    
    Curr Issues Mol Biol

22. MEIRELES S, Dias C, Marques A, Silva J, et al
    Differentiating Upper Tract Urothelial Carcinoma with Synchronous or Metachronous Bladder Cancer.
    Curr Issues Mol Biol. 2026;48:345.
    PubMed         Abstract available
    
    

    
    Curr Oncol

23. HERRMANN S, Gilfrich C, Siepmann S, Rodas Garzaro JR, et al
    Robotic Partial Cystectomy and Extended Pelvic Lymph Node Dissection for Node-Positive Urachal Adenocarcinoma in a 34-Year-Old Woman: A Case Report.
    Curr Oncol. 2026;33:190.
    PubMed         Abstract available
    
    
24. RESENDE SALGADO L, Zaytoun O, Rabie A, Murphy N, et al
    Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions.
    Curr Oncol. 2026;33:225.
    PubMed         Abstract available
    
    

    
    Cyborg Bionic Syst

25. ZHANG Z, Wang L, An Z, Jiang Y, et al
    Hybrid-Driven Bacillus Calmette-Guerin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer.
    Cyborg Bionic Syst. 2026;7:0492.
    PubMed         Abstract available
    
    

    
    Discov Oncol

26. WANG Y, Yu X
    Development and validation of an interpretable prognostic model for bladder cancer based on lactylation associated genes using SHAP analysis.
    Discov Oncol. 2026 Apr 30. doi: 10.1007/s12672-026-05111.
    PubMed         Abstract available
    
    

    
    Eur J Oncol Nurs

27. KANG Y, Zhong G, Lv A, Zhang Y, et al
    Analysis of factors influencing changes in patient-reported quality of life among patients with bladder cancer.
    Eur J Oncol Nurs. 2026;82:103193.
    PubMed         Abstract available
    
    

    
    Eur Urol

28. LU W, Chen L
    Re: Ipilimumab and Nivolumab Followed by Chemoradiotherapy as Bladder-sparing Treatment in Muscle-invasive Bladder Cancer: A Phase 2 Trial.
    Eur Urol. 2026 Apr 23:S0302-2838(26)02098-1. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Eur Urol Oncol

29. PICHLER R, van Creij NCH, Mertens LS, Del Giudice F, et al
    FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma.
    Eur Urol Oncol. 2026;9:220-226.
    PubMed         Abstract available
    
    

    
    Front Bioeng Biotechnol

30. ZHAO Q, Qin Z, Liu R, Zuo K, et al
    Integrate single-cell and transcriptome analyses to explore the prognostic genes related to TRPM4 in bladder cancer.
    Front Bioeng Biotechnol. 2026;14:1773551.
    PubMed         Abstract available
    
    

    
    Front Immunol

31. ORTIZ-BONILLA CJ, Molony RD, Miyamoto H, Messing E, et al
    Bacillus Calmette-Guerin immunotherapy-induced extracellular vesicles promote antitumor immunity in bladder cancer.
    Front Immunol. 2026;17:1707754.
    PubMed         Abstract available
    
    

    
    Front Oncol

32. TENG Q, Cheng S, Chen J, Zhu H, et al
    An exploration of GuaLouQuMaiWan related novel prognostic model and search for potential compound pachymic acid in bladder cancer.
    Front Oncol. 2026;16:1714939.
    PubMed         Abstract available
    
    
33. HAKOZAKI Y, Sugimoto K, Yamada Y, Danno T, et al
    Proteogenomic detection of tumor-specific somatic mutant proteins in urinary extracellular vesicles for non-invasive monitoring of bladder cancer.
    Front Oncol. 2026;16:1808671.
    PubMed         Abstract available
    
    

    
    Future Oncol

34. CELLA L, Finocchiaro A, Slusarczyk A, Krajewski W, et al
    Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.
    Future Oncol. 2026 Apr 27:1-9. doi: 10.1080/14796694.2026.2661768.
    PubMed         Abstract available
    
    

    
    Histopathology

35. LAMMERT SM, Luo W, Zhu AC, Wang P, et al
    PAX8-positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles - A clinicopathologic study of 101 consecutive cases with next-generation sequencing in 20 cases.
    Histopathology. 2026;88:1315-1323.
    PubMed         Abstract available
    
    
36. FARAG MS, Oghbaei N, Hussain J, Lametti A, et al
    A minor high-grade component in non-invasive papillary urothelial carcinoma is not associated with a more indolent behaviour.
    Histopathology. 2026;88:1430-1442.
    PubMed         Abstract available
    
    

    
    IEEE Trans Comput Biol Bioinform

37. REN Y, Wu J, Han F
    Predicting Bladder Cancer Prognosis by Integrating Multiple Omics Data through an Adversarial Autoencoder-based Cox proportional hazards Network.
    IEEE Trans Comput Biol Bioinform. 2026;PP.
    PubMed         Abstract available
    
    

    
    In Vivo

38. FURUBAYASHI N, Tsujita J, Takayama A, Shiraishi Y, et al
    Older Age and Outcomes of Intravesical Bacillus Calmette-Guerin for Non-muscle-invasive Bladder Cancer.
    In Vivo. 2026;40:1585-1594.
    PubMed         Abstract available
    
    

    
    Indian J Tuberc

39. RASCIO L, Borghese O, Minelli F, Sica S, et al
    Common femoral artery pseudoaneurysm due to Mycobacterium Bovis infection following intravescical bacillus Calmette-Guerin therapy.
    Indian J Tuberc. 2026;73:277-279.
    PubMed         Abstract available
    
    

    
    Int J Cancer

40. MANGOLD MH, Baumann G, Wieland VLS, Carl N, et al
    Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled
    Int J Cancer. 2026 Apr 28. doi: 10.1002/ijc.70525.
    PubMed         Abstract available
    
    

    
    Int J Urol

41. MIYAKE M
    Editorial Comment to Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database.
    Int J Urol. 2026;33:e70481.
    PubMed        
    
    

    
    Int Urol Nephrol

42. SAKTHIVEL DK, Prabhakar P, Raja Iyub MJ, Garje R, et al
    Signet ring cell carcinoma of the urachus: survival and pathologic outcomes from the national cancer database.
    Int Urol Nephrol. 2026;58:1745-1751.
    PubMed         Abstract available
    
    

    
    Investig Clin Urol

43. DUARTE S, Felicio E, Bernardo G, Gaboleiro F, et al
    Early complications within 30 days after radical cystectomy: The top seven complications and their predictors.
    Investig Clin Urol. 2026;67:254-262.
    PubMed         Abstract available
    
    
44. HEO JE, Kim J, Jang WS, Sung HH, et al
    Impact of carcinoma in situ of bladder at transurethral resection and radical cystectomy on survival: Retrospective multicenter study.
    Investig Clin Urol. 2026;67:246-253.
    PubMed         Abstract available
    
    
45. CHOI J, Song W, Nam JK, Lim B, et al
    Association of initial transurethral resection staging on survival in radical cystectomy patients.
    Investig Clin Urol. 2026;67:237-245.
    PubMed         Abstract available
    
    

    
    J Int Med Res

46. LI Y, Wei W, Liu C, Lu H, et al
    A multidimensional nomogram integrating immune, inflammatory, and coagulation markers for personalized prognosis in bladder cancer.
    J Int Med Res. 2026;54:3000605261441388.
    PubMed         Abstract available
    
    

    
    J Mater Chem B

47. PENG Z, Huang Z, Nan Z, Yan Y, et al
    A tumor cell membrane-engineered MXene nanoplatform for chemo-photothermal immunotherapy of bladder cancer.
    J Mater Chem B. 2026 Apr 29. doi: 10.1039/d6tb00416.
    PubMed         Abstract available
    
    

    
    J Med Econ

48. BELSEY J, Chrosny W, Lapon J
    Addressing the challenges of health economic modelling in the context of suboptimal evidence base - case study based on a comparison between photodynamic diagnosis and narrow band imaging in non-muscle invasive bladder cancer.
    J Med Econ. 2026;29:1341-1354.
    PubMed         Abstract available
    
    

    
    J Nanobiotechnology

49. ZHONG Z, Wu J, Shang H, Tong Y, et al
    Engineered T cell membrane coated nanoparticles reverse thermo-resistance and reprogram tumor microenvironment to synergistically potentiate bladder cancer photothermal immunotherapy.
    J Nanobiotechnology. 2026 Apr 27. doi: 10.1186/s12951-026-04455.
    PubMed         Abstract available
    
    
50. ZHU C, Liu M, Liu X, Zhang S, et al
    The ZIF-8 nanoplatform targeted delivery of IFI44 siRNA to suppress bladder cancer development via modulating the PI3K/AKT signaling pathway.
    J Nanobiotechnology. 2026 Apr 30. doi: 10.1186/s12951-026-04419.
    PubMed         Abstract available
    
    

    
    J Natl Compr Canc Netw

51. OTANI Y, Otani K, Rodden D, Lemieux M, et al
    PCO26-275: Single Cell RNA-seq of Circulating Tumor Cells in Recurrent Bladder Cancer After Bladder-Sparing Trimodality Therapy.
    J Natl Compr Canc Netw. 2026;24.
    PubMed        
    
    

    
    J Pers Med

52. STERNER P, Gimbergsson S, Johansson M, Alamdari F, et al
    Recurrence Rate After Post-Operative Two-Hour Continuous Bladder Irrigation for Primary Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
    J Pers Med. 2026;16:175.
    PubMed         Abstract available
    
    

    
    J Urol

53. LI EV, Sharma V, Boorjian SA
    Are ctDNA and utDNA the new PSA for Clinically Localized Muscle Invasive Bladder Cancer in the Enfortumab Vedotin/Pembrolizumab Era?
    J Urol. 2026 Apr 29:101097JU0000000000005074. doi: 10.1097/JU.0000000000005074.
    PubMed        
    
    
54. GHOREIFI A, Lotan Y
    Letter: Preoperative ctDNA Predicts Upstaging and Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy.
    J Urol. 2026 May 1:101097JU0000000000005078. doi: 10.1097/JU.0000000000005078.
    PubMed        
    
    

    
    JCO Glob Oncol

55. CASTELLO DIAS CARNEIRO AP, Batista EC, Gomes Bugano DD, Corradi RG, et al
    Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study.
    JCO Glob Oncol. 2026;12:e2500324.
    PubMed         Abstract available
    
    

    
    JMIR Res Protoc

56. GARG T, Lyons T, Rabinowitz K, Gabriel J, et al
    Use of Shared Decision-Making in Non-Muscle-Invasive Bladder Cancer: Protocol for a Scoping Review.
    JMIR Res Protoc. 2026;15:e90101.
    PubMed         Abstract available
    
    

    
    Jpn J Clin Oncol

57. HIROSE K, Yoshida S, Chen W, Yajima S, et al
    Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer.
    Jpn J Clin Oncol. 2026 Apr 29:hyag072. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Nat Commun

58. XIE F, Xie C, Yue H, Cui J, et al
    The association of physical activity with urological cancer risk: a systematic review and meta-analysis.
    Nat Commun. 2026;17:3949.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

59. LLOYD L
    Bladder cancer research is blossoming in Birmingham.
    Nat Rev Urol. 2026 Apr 24. doi: 10.1038/s41585-026-01154.
    PubMed        
    
    

    
    Nutr Cancer

60. SEYYEDSALEHI MS, Hadji M, Rashidian H, Naghibzadeh-Tahami A, et al
    Fatty Acid Intake and Bladder Cancer Risk: A Multicenter Case-Control Study in Iran.
    Nutr Cancer. 2026 Apr 25:1-12. doi: 10.1080/01635581.2026.2658800.
    PubMed         Abstract available
    
    

    
    Pathol Res Pract

61. CHEN H, Yang G, Wei L, Cui Z, et al
    SPI1 inhibits ferroptosis and immune escape of bladder cancer cells by promoting CRYAB expression.
    Pathol Res Pract. 2026;283:156487.
    PubMed         Abstract available
    
    

    
    PeerJ

62. MA L, Tao Y, Cheng L, You C, et al
    Multilayered analysis of cisplatin resistance mechanisms in bladder cancer: from the cell membrane to organelles.
    PeerJ. 2026;14:e21148.
    PubMed         Abstract available
    
    

    
    Photodiagnosis Photodyn Ther

63. SHIGEHISA R, Fukata S, Pustimbara A, Kawada C, et al
    Discordant fibroblast growth factor receptor 3 (FGFR3) expression between photodynamic diagnosis-positive and -negative bladder cancer lesions: An intra-patient paired analysis.
    Photodiagnosis Photodyn Ther. 2026;59:105488.
    PubMed         Abstract available
    
    

    
    Proteomics

64. AHANGAR M, Mischak H, Moulavasilis N, Stravodimos K, et al
    Urinary Peptidomic Signatures Predict Overall and Progression-Free Survival in Bladder Cancer.
    Proteomics. 2026 Apr 27:e70135. doi: 10.1002/pmic.70135.
    PubMed         Abstract available
    
    

    
    Sci Rep

65. SHARIATI S, Mohtadi S, Molavinia S, Salehcheh M, et al
    Empagliflozin enhances cisplatin activity in chemo-resistant EJ138 bladder cancer cells: The importance of anti-diabetic medications in cancer treatment.
    Sci Rep. 2026 Apr 24. doi: 10.1038/s41598-026-49196.
    PubMed        
    
    

    
    Tech Innov Patient Support Radiat Oncol

66. GUBERINA N, Khouya A, Hoffmann C, Fischedick G, et al
    Do AI-based contouring algorithms influence physicians in the online adaptive radiotherapy of patients with bladder cancer?
    Tech Innov Patient Support Radiat Oncol. 2026;38:100401.
    PubMed         Abstract available
    
    

    
    Urol Int

67. SCHEPER V, Berninger L, Schwinger M, Woidich R, et al
    Routine Retrograde Conduitography after Radical Cystectomy for Bladder Cancer: Diagnostic Yield and Clinical Impact.
    Urol Int. 2026 Apr 28:1-10. doi: 10.1159/000552253.
    PubMed         Abstract available
    
    

    
    Urologia

68. SHARMA A, Biswal D, Sharma S, Ravani Thrilochana R, et al
    Laparoscopic radical cystectomy in patients with bladder cancer: A modified technique with reduced morbidity - A comparative study.
    Urologia. 2026 Apr 29:3915603261444885. doi: 10.1177/03915603261444885.
    PubMed         Abstract available
    
    
69. GOLOMB D, Atamna F, Avda Y, Leonov Polak M, et al
    Tumor site as predictors of pathologic progression in high-grade T1 bladder cancer.
    Urologia. 2026 Apr 29:3915603261444890. doi: 10.1177/03915603261444890.
    PubMed         Abstract available
    
    
70. SACCO E, Bizzarri FP
    Comment on: "Comparison of long-term survival for muscle-invasive bladder cancer patients who underwent bladder preservation therapy and radical cystectomy: A systematic review and meta-analysis".
    Urologia. 2026 Apr 28:3915603261445157. doi: 10.1177/03915603261445157.
    PubMed        
    
    

    
    Zhong Nan Da Xue Xue Bao Yi Xue Ban

71. XU L, Pi S, Shen Q, Liu Y, et al
    [Application of whole-process nutritional management based on IKAP theory in patients undergoing radical cystectomy with ileal conduit diversion].
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025;50:2407-2416.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum